CANY
ANIK icon

Caxton Associates (New York)’s Anika Therapeutics ANIK Stock Holding History

Caxton Associates (New York)’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-7,737
Closed -$201K – 398
2023
Q2 		$201K Sell
7,737
-1,416
-15% -$37.9K 0.03% 414
2023
Q1 		$263K Sell
9,153
-12,258
-57% -$365K 0.04% 375
2022
Q4 		$634K Sell
21,411
-22,393
-51% -$637K 0.04% 196
2022
Q3 		$1.04M Buy
43,804
+16,537
+61% +$381K 0.14% 101
2022
Q2 		$609K Buy
+27,267
New +$608K 0.06% 225

Other funds holding ANIK

TI
Trigran Investments Northbrook, Illinois $545M AUM 56.2% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Caxton Associates (New York)'s ANIK Position: Q3 2023 in Review

Caxton Associates (New York) sold out of Anika Therapeutics (ANIK) in Q3 2023, closing a stake of 7,737 shares — an estimated $201K sold.

Caxton Associates (New York) first reported a position in ANIK in Q2 2022 and held it in 5 quarters. The position peaked at $1.04M in Q3 2022. 115 funds tracked by Wall St. Rank hold ANIK as of Q3 2023.

  • Caxton Associates (New York) reported no remaining Anika Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Caxton Associates (New York) sold 7,737 Anika Therapeutics shares in Q3 2023, an estimated $201K.
  • Caxton Associates (New York) first reported a position in Anika Therapeutics in Q2 2022 and held it in 5 quarters.
  • Caxton Associates (New York)'s Anika Therapeutics position peaked at $1.04M in Q3 2022.
  • 115 funds tracked by Wall St. Rank held Anika Therapeutics as of Q3 2023.

Based on Caxton Associates (New York)'s 13F filing for Q3 2023, filed 14 Nov 2023.